336 related articles for article (PubMed ID: 27127301)
41. SOX11 augments BCR signaling to drive MCL-like tumor development.
Kuo PY; Jatiani SS; Rahman AH; Edwards D; Jiang Z; Ahr K; Perumal D; Leshchenko VV; Brody J; Shaknovich R; Ye BH; Parekh S
Blood; 2018 May; 131(20):2247-2255. PubMed ID: 29615403
[TBL] [Abstract][Full Text] [Related]
42. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.
Zhao X; Lwin T; Silva A; Shah B; Tao J; Fang B; Zhang L; Fu K; Bi C; Li J; Jiang H; Meads MB; Jacobson T; Silva M; Distler A; Darville L; Zhang L; Han Y; Rebatchouk D; Di Liberto M; Moscinski LC; Koomen JM; Dalton WS; Shain KH; Wang M; Sotomayor E; Tao J
Nat Commun; 2017 Apr; 8():14920. PubMed ID: 28416797
[TBL] [Abstract][Full Text] [Related]
43. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
[No Abstract] [Full Text] [Related]
44. Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line.
Hagiwara K; Tokunaga T; Iida H; Nagai H
Anticancer Res; 2015 Dec; 35(12):6679-84. PubMed ID: 26637884
[TBL] [Abstract][Full Text] [Related]
45. Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α.
Pontoriero M; Fiume G; Vecchio E; de Laurentiis A; Albano F; Iaccino E; Mimmi S; Pisano A; Agosti V; Giovannone E; Altobelli A; Caiazza C; Mallardo M; Scala G; Quinto I
J Mol Med (Berl); 2019 May; 97(5):675-690. PubMed ID: 30887112
[TBL] [Abstract][Full Text] [Related]
46. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
[TBL] [Abstract][Full Text] [Related]
47. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
Restelli V; Lupi M; Vagni M; Chilà R; Bertoni F; Damia G; Carrassa L
Target Oncol; 2018 Apr; 13(2):235-245. PubMed ID: 29441438
[TBL] [Abstract][Full Text] [Related]
48. Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.
Ahmed M; Lorence E; Wang J; Jung D; Zhang L; Nomie K; Wang M
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723172
[TBL] [Abstract][Full Text] [Related]
49. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
50. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
[TBL] [Abstract][Full Text] [Related]
51. The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway.
Zhang W; Liang X; Gong Y; Xiao C; Guo B; Yang T
Med Sci Monit; 2019 Apr; 25():2599-2608. PubMed ID: 30964854
[TBL] [Abstract][Full Text] [Related]
52. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
[TBL] [Abstract][Full Text] [Related]
53. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
54. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
56. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M; Giró A; Rodriguez V; Fuentes P; Aulitzky WE; van der Kuip H; Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D
J Exp Clin Cancer Res; 2019 Nov; 38(1):446. PubMed ID: 31676012
[TBL] [Abstract][Full Text] [Related]
57. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
[TBL] [Abstract][Full Text] [Related]
58. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
59. Carfilzomib Inhibits Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis.
Zhang YL; Guang MH; Zhuo HQ; Min XH; Yao Q; Gu AQ; Wu SH; Zhang DB; Lu JY; Chen Y; Chen YH; Zhang KJ
Acta Haematol; 2017; 137(2):106-112. PubMed ID: 28208145
[TBL] [Abstract][Full Text] [Related]
60. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.
Shishodia S; Amin HM; Lai R; Aggarwal BB
Biochem Pharmacol; 2005 Sep; 70(5):700-13. PubMed ID: 16023083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]